Natalie Haustrup (N Haustrup)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Topics

Atopic Dermatitis

Respiratory Syndrome Coronavirus

Top Venues

Journal of the European Academy of Dermatology and Venereology : JEADV

Science translational medicine

Infectious diseases and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Adam Reich, Andreas Pinter, Julia-Tatjana Maul, Ronald B Vender, Tiago Torres, A Brnabic, Natalie Haustrup, C Reed, C Schuster, E Riedl
Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Adam Reich, Andreas Pinter, Julia-Tatjana Maul, Ronald B Vender, Tiago Torres, A Brnabic, Natalie Haustrup, C Reed, C Schuster, E Riedl
Speed of Clinical Improvement in the Real-World Setting from Patient-Reported Psoriasis Symptoms and Signs Diary (PSSD): Secondary Outcomes from the Psoriasis Study of Health Outcomes (PSoHO) Through 12 Weeks. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Robert J Benschop, Jay L Tuttle, Lin Zhang, Josh Poorbaugh, Nicole L Kallewaard, Peter Vaillancourt, Melissa Crisp, Thi Ngoc Vy Trinh, Joshua J Freitas, Stephanie Beasley, Montanea Daniels, Natalie Haustrup, Richard E Higgs, Ajay Nirula, Myron S Cohen, Mary Marovich
The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Science translational medicine 14 (655) (2022)
Ramesh Nathan, Imad Shawa, Inmaculada De La Torre, Jennifer M Pustizzi, Natalie Haustrup, Dipak R Patel, Gregory Huhn
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2. Infectious diseases and therapy 10 (4) (2021)